The purpose of this application is to create a research and training program which will allow Dr. Lanfear to develop into an independent clinician-scientist with translational research projects focused on cardiovascular pharmacogenetics. The proposed program will accomplish this goal through completion of the research sroject, technical skills training, didactic coursework focused on genome-wide techniques, and outstanding mentorship. The overall strengths of the proposal are further supported by the quality of the applicant and the relevance and scientific merit of the research project. The applicant has clinical expertise in heart failure [HF), experience in genotyping, advanced training in study design and statistics (culminating in an M.S.), and has shown focus and motivation through successfully completing projects and publishing the results in reputable journals. He would greatly benefit from the proposed coursework in array-based genomic techniques as well as the skills gained via execution of the research project. The research project will enhance his technical skills, allow mentoring, and will generate data for publication and justification of future experiments. It focuses on HF which continues to be an enormous public health problem despite many advances in pharmacotherapy over the past 25 years. There are currently insufficient tools to guide the optimal selection of drug therapy for individuals. The expansion of human genomic information has led to exciting new opportunities for pharmacogenetics to improve drug therapy. One of the most exciting new areas in HF is the natriuretic peptide system. B-type Natriuretic Peptide (BMP) has diagnostic and prognostic importance in HF and is a commercially available therapeutic agent for acute HF exacerbations. Despite its beneficial effects, BMP therapy has several limitations;it is intravenous, expensive, and has potential toxicities. The goal of this project is to define genetic predictors of the efficacy and toxicity of intravenously administered BMP. A candidate gene approach will be taken and sequence data will be correlated with pharmacokinetic, pharmacodynamic, and clinical response parameters. As a mechanistic validation the association of sequence variants with expression level of the candidate genes and quantity of protein products will be assessed in human kidney tissue samples. The overall program will not only define functional predictive variants, but will advance the candidate's career while setting the ground work for follow-up studies of pharmacogenetically directed BNP therapy.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-R (F1))
Program Officer
Scott, Jane
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Henry Ford Health System
United States
Zip Code
Lanfear, David E; Chow, Sheryl; Padhukasahasram, Badri et al. (2014) Genetic and nongenetic factors influencing pharmacokinetics of B-type natriuretic peptide. J Card Fail 20:662-8
Williams, L Keoki; Padhukasahasram, Badri; Ahmedani, Brian K et al. (2014) Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 99:3160-8
Hayek, Sami; Canepa Escaro, Fabrizio; Sattar, Assad et al. (2013) Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol 111:532-9
Lanfear, David E; Sabbah, Hani N; Goldsmith, Steven R et al. (2013) Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail 6:47-52
Srivastava, Ajay V; Hrobowski, Tara; Krese, Lori et al. (2013) High rates of false-positive hepatitis C antibody tests can occur after left ventricular assist device implantation. ASAIO J 59:660-1
Lanfear, David E; Sunkara, Bipin; Li, Jia et al. (2013) Association of genetic variation with gene expression and protein abundance within the natriuretic peptide pathway. J Cardiovasc Transl Res 6:826-33
El-Refai, Mostafa; Peterson, Edward L; Wells, Karen et al. (2013) Comparison of ?-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail 19:73-9
Hrobowski, Tara; Lanfear, David E (2013) Ventricular assist devices: is destination therapy a viable alternative in the non-transplant candidate? Curr Heart Fail Rep 10:101-7
Singh, Gurjit; Peterson, Edward L; Wells, Karen et al. (2012) Comparison of renal predictors for in-hospital and postdischarge mortality after hospitalized heart failure. J Cardiovasc Med (Hagerstown) 13:246-53
Lanfear, David E; Hrobowski, Tara N; Peterson, Edward L et al. (2012) Association of *-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail 5:202-8

Showing the most recent 10 out of 14 publications